LUCIUS 卢修斯 帕克替尼 Pacritinib骨髓纤维化

帕克替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Pacritinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

骨髓纤维化

Each capsule contains Pacritinib citrate
140.65 mg equivalent to Pacritinb ... 100m

LUCIUS

LuciPac is a kinase inhibitor indicated for

PHARMACEUTICALS

the treatment of adults with intermediate or
high-risk primary or secondary (nost.
polycythemia vera or post-essential
Thrombocythemia) myelofibrosis with a

LuciPac

platelet count below 50 x10 L
Dosage and Use:
+ Recommended dosage is 200 mg orally

Pacritinib Capsules

FDA批准

.May be taken with or without food.
Storysa ns
Storage: in a dry place and store at 20°℃ to
25°C.

100mg

Warning:
Keep medicine out of reach of Children. D

Rx Only

PLEASE SEE PACKAGE INSERT

权威认证

Manufactured and Marketed by
LUCIUS

Thongmang village, Xaythany district,
Vientiane Capital, Laos
warning : lo be sold by retail on prescripuion
paysicians oniy, and as directed

120 Capsules

口碑质量

适应症:
帕克替尼是一种激酶抑制剂,适用于治疗血小板计数低于
50×10°/L的中危或高危原发性或继发性(真性红细胞增多症
后或原发性血小板增多症后)骨髓纤维化的成人患者。
推荐剂量:
1 、 推 荐 剂 量 为 每 日 两 次 , 每 次 口 服 200mg
2、可与食物同服或单独服用。